Tag: immunotherapy trial endpoints

Designing and Managing Immunotherapy Clinical Trials in Oncology

August 14, 2025

Designing and Managing Immunotherapy Clinical Trials in Oncology Comprehensive Guide to Immunotherapy Clinical Trial Design in Oncology Introduction to Immunotherapy Trials Immunotherapy has transformed the landscape of oncology by harnessing the patient’s own immune system to recognize and eliminate cancer cells. From checkpoint inhibitors to CAR-T cells and neoantigen vaccines, immuno-oncology (IO) therapies are expanding…

Immunotherapy Studies, Oncology Clinical Trials

Bispecific Antibodies in Oncology Trials: Design and Challenges

August 6, 2025

digi

Bispecific Antibodies in Oncology Trials: Design and Challenges Designing and Managing Clinical Trials for Bispecific Antibodies in Oncology Introduction to Bispecific Antibodies in Oncology Bispecific antibodies (BsAbs) are engineered to recognize two different antigens or epitopes simultaneously, offering unique mechanisms of action such as redirecting T cells to tumor cells or blocking multiple signaling pathways….

Immunotherapy Studies, Oncology Clinical Trials

Early vs Late Phase Trials in Immuno-Oncology

August 3, 2025

digi

Early vs Late Phase Trials in Immuno-Oncology Comparing Early and Late Phase Trials in Immuno-Oncology Introduction to Immuno-Oncology Clinical Development Immuno-oncology (I-O) has transformed cancer treatment, introducing therapies that harness the immune system to recognize and destroy tumor cells. The clinical development of I-O agents follows the traditional phase-based pathway—Phase I (early), Phase II, Phase…

Oncology Clinical Trials, Phase-Specific Oncology Trials